Diabetes Connections | Type 1 Diabetes
The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
info_outline
800 Episodes Later: What I've Learned From the Diabetes Community
07/07/2026
800 Episodes Later: What I've Learned From the Diabetes Community
We're celebrating 800 episodes of your stories. News, interviews, information, community and much more. To celebrate, we're doing something a little different. Instead of interviewing a guest, Stacey is in the hot seat as podcast producer and friend Jon Gay asks questions submitted by listeners, community members, and some familiar voices from the diabetes world. Stacey looks back on how the podcast started, the moments that shaped it, and the biggest changes she's seen in diabetes technology and care over the last decade. She shares stories from behind the scenes, talks about raising Benny from toddler diagnosis to independent adulthood, and reflects on what continues to inspire her about this community. Along the way, you'll hear about: The breakthroughs that have made the biggest difference for people with diabetes What it's really like to cover diabetes news week after week The guests she'd still love to interview The topics that spark the most passionate debate How the diabetes community continues to show up for one another Most of all, this episode is a thank you. Whether you've been listening since Episode 1 or just found the show last week, thank you for being part of Diabetes Connections. This community has made 800 episodes possible, and Stacey is grateful for every conversation, every question, and every listener along the way. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41985770
info_outline
In the News... Tzield, Retatrutide, New Clues About Type 1 and more!
06/30/2026
In the News... Tzield, Retatrutide, New Clues About Type 1 and more!
It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Transcript & links: Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/ XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy. In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings. Following is a transcript of his remarks: What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses. Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity]. And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%. However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment. Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment. Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure. And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin. So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment. So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it’s not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: “The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients.” https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance. Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They’ve added that to include people diagnosed with type 1 who’ve been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care. Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing. The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season. https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/
/episode/index/show/diabetesconnections/id/41910570
info_outline
Inside Diabetes Will's Way: Helping Families Afford the Care They Need
06/23/2026
Inside Diabetes Will's Way: Helping Families Afford the Care They Need
What if I told you that there’s a diabetes organization that will write a check to help a family pay for the supplies they need right now. helps families afford insulin pumps, CGMs, and other diabetes technology when insurance falls short. I’m talking to Will Oberndorfer, the company’s namesake, as he takes over running the non profit from his mother and godmother, who founded it more than a decade ago. We talk about the growing number of young adults struggling to pay for care, why some families are considering going without insurance altogether, and the surprising trends his organization is seeing from the front lines of diabetes affordability. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episode with Lisa Oberndorfer Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41723210
info_outline
In the News... Tzield approved for newly diagnosed T1D, GLP-1 studies for type 1, ADA 2026 highlights and more!
06/16/2026
In the News... Tzield approved for newly diagnosed T1D, GLP-1 studies for type 1, ADA 2026 highlights and more!
It's In The News - a look at the top diabetes stories and headlines happening now! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcript: fall Detroit and Seattle. Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that’s what we used to just call type 1. It’s the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it’s the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells. The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You’ve probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That’s , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet’s current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It does not require carb-counting or insulin bolusing ahead of meals. Physicians also don’t need to program the starting settings. XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that’s all to come right after this. -- Back to the news.. XX Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology. -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings. XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They’re also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg’s family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. “Becoming a professional tennis player was always my dream,” Zverev shared in an article posted by Medtronic. “Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That’s why I’m partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want.” He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries.”
/episode/index/show/diabetesconnections/id/41649685
info_outline
Inside the ADA Scientific Sessions Protest & Aftermath with Dr. Desmond Schatz
06/12/2026
Inside the ADA Scientific Sessions Protest & Aftermath with Dr. Desmond Schatz
What happened at ADA? It’s not the research or the science, but the response to a protest that’s been getting the biggest headlines. My guest, Dr. Desmond Schatz was scheduled to come on the podcast this week to talk about early, population-level screening for type 1 diabetes. Dr. Schatz was one of the five people asked to leave the ADA conference after passing out an editorial. The ADA has sinced apologized a coupe of times.. you’ll hear the whole story form Dr. Shatz, we’ll get into the follow up since our conversation, and we do talk about screening. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Apology from ADA president Chuck Henderson: The Diabetes Care The second Diabetes Care More about this story and the resignations here: Learn about our in-person events here: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41616290
info_outline
T1D and Celiac: Practical Tips from a Family Who's Been There
06/09/2026
T1D and Celiac: Practical Tips from a Family Who's Been There
This week on Diabetes Connections. When Samantha Merwin found out her son was diagnosed with celiac on top of type 1 diabetes it seemed overwhelming. Clearing out your pantry, replacing your toaster, rethinking every restaurant meal, and teaching your child to advocate for themselves all over again. This week, we're talking about life with both type 1 and celiac disease, and the free resources one mom created because she couldn't find the help her family needed. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Elbow Bump Kid Celiac Guide: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41571675
info_outline
BONUS: Dexcom updates & news from ADA with CEO Jake Leach
06/07/2026
BONUS: Dexcom updates & news from ADA with CEO Jake Leach
In this BONUS episode of Diabetes Connections.. I’m talking to Dexcom CEO Jake Leach. Lots of news from Dexcom as they presented new information this weekend at the annual ADA Conference. Did you also know that the G6 will stop being made in less than a month, that Dexcom is developing a new product for hospitals, why they’re talking about potassium and we look at the customer advisory counsel report. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Advisory Counsel Report: Dexcom Investor Report (with the hospital device and potassium info): Dexcom Connect Study: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41564555
info_outline
BONUS Episode: Afrezza Approved for Kids: A Deep Dive Into Inhaled Insulin with INHALE-1 Lead Investigator Dr. Jamie Wood
06/04/2026
BONUS Episode: Afrezza Approved for Kids: A Deep Dive Into Inhaled Insulin with INHALE-1 Lead Investigator Dr. Jamie Wood
On this bonus episode of Diabetes Connections.. a deep dive into inhaled insulin for kids. Last week the FDA approved Afrezza for kids six and older – it’s been approved for adults for more than a decade – and boy did you have questions. We’re talking to Dr. Jamie Wood, pediatric endocrinologist and principal investigator of the INHALE-1 trial that helped lead to this approval. We’re talking about what that studied showed, what the approval means, how to use Afrezza, and a bunch of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our prevous episodes on Afrezza: Our previous episode with Dr. Jamie Wood: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41522955
info_outline
In the News.. Inhaled Insulin Approved for Kids, CGM + Ketone Monitor, Food Coloring & Diabetes Study, Device Recalls and more!
06/02/2026
In the News.. Inhaled Insulin Approved for Kids, CGM + Ketone Monitor, Food Coloring & Diabetes Study, Device Recalls and more!
It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcripts: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We’ll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We’ve got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind’s afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients. The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: “Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option.” Lots more to come on this – we’re working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it’s such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They’re calling this Libre Duo and Libre Duo 10 Day, and it’s designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic. Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action. The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling. Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said. People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics’ interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association’s Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet’s patch pumps on the market. It would have a 200-unit insulin reservoir. Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall. https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it’s coverage list – with it’s Caremark PBM. They also added Foundayo, Lilly’s obesity pill. CVS had dropped Lilly’s Zepound last summer but kept competitor Wegovy. It’ll be back at Caremark October first. All three of the nation's largest pharmacy benefit managers now cover Lilly's full obesity medicine portfolio. More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers. Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). “Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence,” the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women. Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea. While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. “Tidepool has always focused on making diabetes data more accessible and actionable,” said Brandon Arbiter, CEO. “We’re excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters.” Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool’s existing EHR integration capabilities. Direct Connect is part of Tidepool’s ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes. The feature is now available in the Connection Hub of the Epic Showroom. https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX
/episode/index/show/diabetesconnections/id/41492405
info_outline
SAB Bio’s Safeguard Study: A New Way to Approach Type 1 Diabetes Delay and Prevention
05/26/2026
SAB Bio’s Safeguard Study: A New Way to Approach Type 1 Diabetes Delay and Prevention
What's next in the attempt to change the course of type 1 diabetes? SAB Bio says they’re looking to redefine what it means to get a type 1 diabetes diagnosis. They’re trialing a drug right now preserve the patient's ability to make their own insulin.. and maybe even allow repeat dosing. I’m talking to Dr. Michael Haller from the University of Florida and Sam Reich the CEO of SAB Bio about what makes this different and what their big hopes are. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41406730
info_outline
In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more!
05/19/2026
In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more!
It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcript: XX Dexcom announces some features of it’s next generation CGM – the G8. We’ve been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they’re calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It’s an interesting space to watch.. btw, analyte is just a medical word for the specific thing you’re measuring – the target of the test you’re running. we’re going to hear that word a lot I think.. Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that’s investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack’s active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology. PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics’ CGM. PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems. Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It’ll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/-- XX Diabeloop just got CE Mark approval for DBLG2 integrations – it’s latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it’s integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps “available soon.” Running on a user’s smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/ XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis. METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively. "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease. XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes. The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. “This study is the tip of the iceberg,” said Dr. Evans-Molina. “We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data.” https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients. “This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied,” said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center. Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival. What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report. The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes. GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment. “Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings,” said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health. What’s next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials. “Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making,” Fuemmeler said. XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. “We would think that chronic cannabis users would be eating more and weigh more, but it’s just the opposite,” DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body’s endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here’s what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes. One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes
/episode/index/show/diabetesconnections/id/41331730
info_outline
“Every trip is a learning experience” Advice from travel-loving T1D parents, Sarah Steward Holland and Nicholas Holland
05/12/2026
“Every trip is a learning experience” Advice from travel-loving T1D parents, Sarah Steward Holland and Nicholas Holland
Let’s talk travel! It’s that time of year when we start getting ready for family vacations and trips big and small. Whether you’re driving to the beach for a long weekend, heading to a week-long family reunion or taking that dream vacation overseas, diabetes makes everything just a little bit more complicated. I’m talking to Sarah Stewart Holland and Nicholas, parents of three boys, one with type 1. Nicholas has put together a great travel guide and we have a helpful and eye opening conversation about taking T1D along for the ride. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Learn more about our Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41248805
info_outline
In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more!
05/05/2026
In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more!
It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more. Announcing Community Commericals! Learn how to Don't miss our in-person events: Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/ XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community. It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. XX Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028. XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage. Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company’s Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it’s the episode just before this one. XX Switching CGMs didn’t make a measurable difference for adults using MiniMed’s pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. “When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more,” Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. “Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want.” I’m including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. “More research is needed to see if there are other factors that are associated with risk reduction.” https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world’s first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study. The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can’t necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison. The Virginia senator wrote on the social platform X, “As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we’ve received. Thank you to everyone for your kind words.” Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were “heartbroken beyond words” by their daughter’s passing. On Monday, the former Virginia governor said his daughter “was a deeply empathetic and engaged person” and that “as recently as the day she passed, she was full of ideas and suggestions” for him, including how he could improve his social media presence. “She used to say to me: ‘Dad, you have the power — you have to use it.’ She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways,” he added. “If I can find any solace during this time, it’s that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy’s name.” Warner concluded, “I look forward to returning to the Senate this week and continuing that essential work.” Madison Warner is survived by two younger sisters. An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC’s National Diabetes Statistics Report. An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes. Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D. The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.
/episode/index/show/diabetesconnections/id/41148080
info_outline
Inside Tandem’s Next Chapter: Tubeless Mobi, 7-Day Wear & More with VP of Product Management Marisa Fienup
05/01/2026
Inside Tandem’s Next Chapter: Tubeless Mobi, 7-Day Wear & More with VP of Product Management Marisa Fienup
This week on Diabetes Connections.. an update from Tandem Diabetes. Quite a few approvals and advances have already happened for Tandem this year, as the company looks ahead to the launch of their latest product, the Mobi Tubeless, not yet FDA approved. I’m talking to Marisa Fienup VP of Product Management about how this product is different from the original Mobi, the incorporation of the approved 7-day infusion set, asking your questions and more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41068910
info_outline
The Fight to Save Levemir: Inside the Grassroots Push to Protect Insulin Choice
04/28/2026
The Fight to Save Levemir: Inside the Grassroots Push to Protect Insulin Choice
In 2024 Novo Nordisk announced it would discontinue Levimir insulin.. leaving many people scrambling and kind of stunned. There’s no other insulin on the market quite like this long-acting – and it turns out the community wasn’t letting it go without a fight. My guests are going to tell you more about why. I’m taking to Alison Smart, founder of Choice – her daughter lives with type 1 as well as two doctors: Florence Brown and Amy Valent. Dr. Brown is Co-Director Joslin and BIDMC Diabetes in Pregnancy Program, Assistant Professor of Medicine, Harvard Medical School. Dr. Valent Assistant Professor of Obstetrics and Gynecology, School of Medicine at Oregon Health and Science University. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/41017450
info_outline
BONUS Episode: TempraMed wants to pair smart insulin tracking with temperature protection
04/24/2026
BONUS Episode: TempraMed wants to pair smart insulin tracking with temperature protection
I’ve been talking to the folks at VIVI Cap for a few years now, it’s been fun watching their progress. I wanted to catch up and find out more about what they’ve been up to when it comes to insulin storage – especially as we get closer to the hot summer months. They launched new products in the last year – smart insulin storage that helps you track dosing and a new case with more cooling protection. My guest is Ron Nagar, the founder and CEO of TempraMed, the company that makes the VIVI Cap. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40989315
info_outline
In the News.. Stem Cell Research Update, New Patch Pump Approved, GLP-1 Resistance Studied, Big Win T1D School Kids and more!
04/21/2026
In the News.. Stem Cell Research Update, New Patch Pump Approved, GLP-1 Resistance Studied, Big Win T1D School Kids and more!
It's In the News! Every other week we bring you the top diabetes stories and headlines happening now. This week's top stories: stem cell reserach updates, the Pivot patch pump gets FDA approval, GLP-1 Resistance research moves forward, T1D kids in VA get a big win, time of day for exercise matters, and much more! Don't miss our 2026 events - Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40934540
info_outline
Eversense 365: Pump Integration and Real-Life Use For the One-Year CGM
04/14/2026
Eversense 365: Pump Integration and Real-Life Use For the One-Year CGM
We've got an update on Eversense—the CGM that sits just below the skin and lasts a year. This is the first time we’re talking to the folks from Senseonics, the company that makes Eversense, since they spun off from Ascensia. What's changed? It’s also the first time, we’re talking to someone who uses Eversense with an insulin pump – it’s now compatible with the twiist pump. I ask your questions about all of this – how’s the pump integration in real life, when will the next iterations of Eversense be out, their success in the type 2 market and much more. We're talking to Chief Commerical Officer Brian Hansen and Paris Hicks, a woman who uses the twiist system with the Eversense 365 CGM. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40832540
info_outline
More Than Babysitting: The Power of Type One Together with Raquel Baron
04/10/2026
More Than Babysitting: The Power of Type One Together with Raquel Baron
Today on Diabetes Connections.. a bonus episode all about finding support and community online and in real life. Seems to be a theme lately and I could NOT be happier. Type One Together started with one college student, a few babysitting jobs, and a realization that there was a need. Type One Together has become something much bigger – they’ll still help you find a sitter but they’re also a hub for T1D info, support and gatherings. I’m talking to the founder, Raquel Baron, about how they got there, what kind of help they provide and what’s next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about - use promo code "connections" to save Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40794115
info_outline
In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!
04/07/2026
In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Stacey mentioned these two groups: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40737615
info_outline
Grownup T1Ds: The Missing Support for Adults Living with Diabetes
03/31/2026
Grownup T1Ds: The Missing Support for Adults Living with Diabetes
There’s a reason we don’t call it juvenile diabetes anymore. We all know you grow up and T1D doesn’t go anywhere, and that you can be diagnosed at any age. But it often feels like adults are forgotten. I hope that’s not the case here—but I hear it all the time in the broader community. Kelly Dawes is working to change that. She’s started GrownUp T1Ds, a community built specifically for adults who’ve been living with type 1 for years and are finally finding connection, understanding, and support in a way they may never have had before. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40668025
info_outline
In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
03/24/2026
In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page transcript with links: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who’s in Vegas? I’ll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It’s one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it. XX Researchers in Japan say they’ve developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice’s blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests XX Lilly says it’s next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study’s second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also “very pleased” with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide’s A1C reduction doesn’t appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person’s appetite and satisfaction with food than other treatments. XX The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It’s about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times. Researchers noted that the body’s response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide. Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years. Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it’s the world’s first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife’s (formerly Ypsomed Diabetes Care’s) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study. https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.
/episode/index/show/diabetesconnections/id/40579645
info_outline
Are We Finally Taking Mental Health Seriously in Diabetes Care?
03/17/2026
Are We Finally Taking Mental Health Seriously in Diabetes Care?
We all know how important mental health is but unless you are VERY lucky, you’re on your own. There are the rare programs out there for pediatric endocrinology and we’ve got one of the best Dr. Taylor Stephens is a pediatric psychologist with the Cleveland Clinic who specializes in pediatric endocrinology conditions. She’s here to share what we can all do, right after diagnosis, and years later to support our kids and ourselves, if you're a caregiver or an adult living with type 1 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about the Use promo code "dmhconnections" to save 15% off your ticket Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40489685
info_outline
BONUS Episode: Dexcom Updates From ATTD with Jessica Castle, VP of Medical Affairs
03/15/2026
BONUS Episode: Dexcom Updates From ATTD with Jessica Castle, VP of Medical Affairs
Bonus episode! I had the opportunity to talk to the folks at Dexcom about their presentations at ATTD and I wanted to bring you the interview sooner rather than later. ATTD is the Advanced Technology and Treatments for Diabetes conference, this year it took place in Barcelona. If you’re new around here, there are a few big diabetes conferences where studies are presented and news is made. ATTD in spring, ADA and ADCES in summer and a few more scattered here and there. We’ll be sharing more from ATTD in upcoming interviews with other tech companies. But today I’m talking to Jessica Castle, VP of Medical Affairs at Dexcom – she’s also an adult endocrinologist with a lot of clinical trial experience. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40486495
info_outline
In the News… $3 Semaglutide?, New Stem Cell Partnership, “Lyla’s Law” Debate, Patient-Led Insulin Dosing in Pregnancy, FDA GLP-1 Crackdown, and more!
03/10/2026
In the News… $3 Semaglutide?, New Stem Cell Partnership, “Lyla’s Law” Debate, Patient-Led Insulin Dosing in Pregnancy, FDA GLP-1 Crackdown, and more!
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, “Lyla’s Law” Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page transcript with links: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it’s very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed ‘Lyla’s Law’, which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries. Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make “false or misleading” claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.” https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical’s facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical’s products. Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May. XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025. Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications. Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin. Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits. The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control. Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders. The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible. Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. “Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes,” says Dr. Jennifer Snaith, endocrinologist and co-lead of the study. Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it’s secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors. https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he’d stepped away for a medical leave. (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer’s return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it . SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement. Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google’s hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016. https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel’s proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care’s Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem’s Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year. Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025. Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/
/episode/index/show/diabetesconnections/id/40372725
info_outline
Fixing the Most Overlooked Problem in Diabetes: Your Skin
03/03/2026
Fixing the Most Overlooked Problem in Diabetes: Your Skin
Why don’t we talk about our skin more?! When you or your child is diagnosed with diabetes, you quickly realize the skin is in for a rough time. Endless pokes from needles, infusion sets, CGM wires. You make it work, but what if there was a better way? I’m talking Marie Schiller and Kent Manson – they’ve teamed up to help with a solution now and one they’re working on for the future. The available now treatment is Site Hero – a recovery patch to help sites heal.. and – for the future - a way to scan an area and help identify better injection or infusion sites at home. This is a great and practical conversation. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40280880
info_outline
In the News... Islet cell transplants update, implantable insulin pump moves forward, Olympics monitored GLP-1s and more!
02/24/2026
In the News... Islet cell transplants update, implantable insulin pump moves forward, Olympics monitored GLP-1s and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcription with links: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I’m just back from MNO DC and I’m exhausted. But it’s the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that’s our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/ Okay.. our top story this week: XX An “immune system reset” eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells. After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed. Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon’s drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she’s off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month’s worth of doses in a single pen.. and it’s multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company’s direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly’s popular diabetes medication, Mounjaro – which is the same medication as zepbound, they’re both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html XX For years, researchers have observed that people who live at high elevations, tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that’s implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – “modern” CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal’s system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That’s the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don’t take insulin. CEO Jake Leach told investors on Thursday that the company has been “sitting here waiting for a coverage decision” from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs. In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic’s separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes. "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition. The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. XX That’s it for in the news!
/episode/index/show/diabetesconnections/id/40205855
info_outline
“It’s incredibly exciting” - What’s next for Tidepool with CEO Brandon Arbiter
02/17/2026
“It’s incredibly exciting” - What’s next for Tidepool with CEO Brandon Arbiter
Tidepool was founded in 2013, part of the incredible era of DIY diabetes progress, and has since helped change how hundreds of thousands of people with diabetes see and use their data. I’m talking to CEO Brandon Artibter about how open-source innovation became FDA-cleared technology, and what’s next.. including a new partnership with Oura Ring to study sleep, activity, and menstrual cycles, and continued work with Tidepool Loop. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes with Tidepool, including the announcment of bringing Loop to the FDA back in 2018! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/40114890
info_outline
In the News... Trump RX, T1D at the Olympics & Superbowl, Ozempic pill launches soon, and more!
02/10/2026
In the News... Trump RX, T1D at the Olympics & Superbowl, Ozempic pill launches soon, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcription with links: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms’ Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it’s always amazing how many people hear of these event last minute. That’s fine, they’re welcome! But if you’re thinking of attending a future event – registration is open for We’re going to Nashville next March 6-7 and Detroit in September – no need to wait. And we’ve got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old. Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she’d already been to several Olympics. We wish them all the best! XX The government website TrumpRx.gov is live.. the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: “If you have insurance, check your co-pay first — it may be even lower.” For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly’s insulin lispro – and it’s the same price as you’d find through Illy’s insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other. I’d suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices XX Dexcom is rolling out what they’re calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks. XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company’s quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA. The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA. The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association’s Scientific Sessions. The company also does not expect the warning letter to affect its financial results. XX Sequel Med Tech is reviewing co-founder Dean Kamen’s ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein’s island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - “Sequel’s Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes,” Kamen has not issued a statement regarding his reported connection to Epstein. https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update. Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors. XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this.. I’m excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes. Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience. They’re also launching the MiniMed 780G system Pump Evaluation Program. This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They’ll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that’s European clearance. This comes on the heels of the launch of Eversense 365 with Sequel Med Tech’s twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas’s becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6. The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.
/episode/index/show/diabetesconnections/id/40042615
info_outline
The FDA pulled it, but the diabetes community wouldn’t let it go. How the T1D1 app made a comeback
02/03/2026
The FDA pulled it, but the diabetes community wouldn’t let it go. How the T1D1 app made a comeback
Two years ago the FDA pulled down just about every insulin calculator app. A lot of them just disappeared, rather than seek official approval, but one of them – created by a teenager with type 1 – is back. I’m talking with Drew and Mike Mendelow about a free and ad-free insulin-dose calculator app. They share what it was like to navigate the FDA process, how they go international help, and what’s next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page
/episode/index/show/diabetesconnections/id/39945190